Cardiomyopathy caused by lamin A/C gene (LMNA) mutations (hereafter referred as LMNA cardiomyopathy) is an anatomic and pathologic condition associated with muscle and electrical dysfunction of the heart, often leading to heart failurerelated disability. There is currently no specific therapy available for patients that target the molecular pathophysiology of LMNA cardiomyopathy. Recent studies suggested that nicotinamide adenine dinucleotide (NAD + ) cellular content could be a critical determinant for heart function. Biosynthesis of NAD + from vitamin B3 (known as salvage pathways) is the primary source of NAD + . We showed here that NAD + salvage pathway was altered in the heart of mouse and human carrying LMNA mutation, leading to an alteration of one of NAD + co-substrate enzymes, PARP-1. Oral administration of nicotinamide riboside, a natural NAD + precursor and a pyridine-nucleoside form of vitamin B3, leads to a marked improvement of the NAD + cellular content, an increase of PARylation of cardiac proteins and an improvement of left ventricular structure and function in a model of LMNA cardiomyopathy. Collectively, our results provide mechanistic and therapeutic insights into dilated cardiomyopathy caused by LMNA mutations.
Introduction
Nicotinamide adenine dinucleotide (NAD) is a metabolic cofactor found in cells either in its oxidized (NAD + ) or reduced (NADH) form. NAD + can be synthesized from various precursors.
Biosynthesis from nicotinic acid or nicotinamide (NAM)-both present in our diet as vitamin B3-is the primary source of NAD + (1) (2) (3) . This pathway, also known as the salvage, is important for NAD + homeostasis. There is another NAD + precursornicotinamide riboside (NR)-that enhances NAD + levels through the salvage pathway when catalyzed by nicotinamide riboside kinase (Nmrk) (4, 5) . In mammals there are two Nmrk enzymes, Nmrk1 and Nmrk2, the latter being highly restricted to muscle. In the salvage pathway of NAD + biosynthesis, nicotinamide phosphoribosyltransferase (Nampt) was identified as a rate-limiting enzyme that converts NAM to nicotinamide mononucleotide (NMN) (6) . NAD + is then synthesized from NMN by NMN adenylyltransferase (Nmnat) (7) . Studies have indicated that NAD + content is a critical determinant for heart function and structure (8, 9) and that Nampt may play an important role in the development of dilated cardiomyopathy (DCM) (10) . In models of DCM, modulation of the different actors of the NAD salvage improves cardiac function (11) (12) (13) . DCM is characterized by dilatation and systolic dysfunction of the left or both ventricles (14) . The ventricular walls become thin and stretched, compromising cardiac contractility and resulting in altered left ventricular function. Despite current strategies to aggressively manage DCM, the disorder remains a common cause of heart failure and a prevalent diagnosis in individuals referred for cardiac transplantation. Mutations in LMNA encoding nuclear lamin A/C (15) were reported to cause DCM (hereafter referred to LMNA cardiomyopathy) (16, 17) . Despite our gaps in understanding many of their fundamental functions, much of the current research on the lamin A/C is focused on how mutations within these proteins cause DCM. We asked here whether NAD + salvage pathway is altered and could play a role in the development of LMNA cardiomyopathy.
Results

Alteration of NAD + salvage pathway in LMNA cardiomyopathy
To explore the role of NAD + salvage pathway in the development of DCM, we studied a mouse model that displays an Lmna mutation changing the histidine in position 222 into a proline (18) . The male mice develop a progressive contractile dysfunction (Supplementary Material, Table 1 ), cardiac remodeling and die by 32-34 weeks of age (18) . Lmna p.H222P corresponds to a human disease-causing mutation associated with DCM (19) . Given that a consequence of altered NAD + salvage pathways would lead to an aberrant cellular NAD + content (Fig. 1A) S2A and S2B ). The same expression pattern of these key genes was also found in other mouse models of inherited DCM (GEO accession number: GSE54838 and GSE17478) ( Fig. S1C ) (21, 22) . We obtained samples of heart tissue from two human subjects with LMNA cardiomyopathy obtained after cardiac transplantation. Control heart samples were obtained from age-matched human subjects without LMNA mutation. We showed decreased expression of Nampt and increased expression of Nmrk2, in heart tissue of the patients with LMNA mutations compared with control subjects (Fig. 1F) . Taken together these results showed that the metabolism of NAD + is altered in LMNA cardiomyopathy.
Rescue of cardiac NAD + content by NR improves cardiac function
Given that the expression of Nmrk2 was increased in heart from Lmna H222P/H222P mice, we tested whether NR, the substrate for Nmrk2 (23) , could increase NAD + content in the heart and therefore, blunt the development of left ventricular dysfunction. Lmna H222P/H222P mice were fed with NR-supplemented diet (400 mg/kg/day), starting at 17 weeks of age for 9 weeks duration ( Fig. 2A) (Fig. 2C) . Cardiac structure and function (mean ± standard error of means) of Nampt and Nmrk2 (relative to ERK1/2). *P-value ≤ 0.01. (F) Immunoblots showing Nampt and Nmrk2 protein levels in hearts from controls (n = 2) and LMNA patients (n = 2). The bar graphs represent protein relative expression (mean ± standard error of mean) of Nampt (relative to ERK1/2).
were assessed by echocardiography after 4 weeks of treatment and at the end of the treatment in the four different groups of mice. Whiskers (Tukey method) extend down to the minimum value and up to the maximum value. ***P-value ≤ 0.0001, NS: non significant.
of cardiac remodeling compared with chow diet-fed animals ( Fig. 2E) . NR-fed Lmna H222P/H222P mice exhibited a decreased mRNA expression of Nmrk2 but Nampt mRNA expression was unchanged, compared with chow diet-fed Lmna H222P/H222P (Fig. S3A) . In a pilot study, we assessed the effect of NR treatment on survival. The mean survival was significantly prolonged in NR-fed Lmna H222P/H222P mice compared with chow diet-fed mice (Fig. 2F ). Taken together, these results showed that NR supplemented diet is efficient to partially restore the left ventricular function and increase the survival in a mouse model of LMNA cardiomyopathy. A critical question relevant to potential treatment of patients with NR regards their effectiveness after the onset of cardiac dysfunction. To help answer this question, we assessed the benefit of NR after dilatation and decreased cardiac fractional shortening have already occurred. Lmna H222P/H222P mice were treated with NR (daily oral dose, 400 mg/kg per day), starting when left ventricular fractional shortening was significantly lowered (30%) compared with WT mice. NR increased NAD + content in both liver and heart compared with placebo ( Fig. 2H.a) (Fig. 3A) . Lmna H222P/H222P mice treated with NAM did not exhibit changes of their NAD + content in both liver and heart compared with placebo-treated animals (Fig. 3B) . Left ventricular structure and function were assessed by echocardiography after 4 weeks of treatment and at the end of the NAM treatment. Compared with placebo-treated Lmna H222P/H222P mice, NAM-treated Lmna H222P/H222P mice had no significant changes in left ventricular end-systolic and left ventricular end-diastolic diameters as well as fractional shortening (Fig. 3C and D, Table 2 ). NAM-treated Lmna H222P/H222P mice had no changed expression of cardiac Myh7, Nppa and Col1a2 (Fig. 3E) . Thus, our data showed that treating Lmna H222P/H222P mice with NAM is not efficient to restore the cardiac NAD + content and the cardiac left ventricular function.
Decreased cardiac NAD + content alters global PARylation
We then asked the consequences of decreased cardiac NAD + on sirtuin 1 (SIRT1) and Poly(ADP-ribose) polymerase 1 (PARP-1) activities. The sirtuins are protein deacetylases, which play roles on mitochondria metabolism (7, 24) . The NAD + level has been shown to activate SIRT1, which regulates mitochondria biogenesis through the deacetylation of target proteins. We showed that the level of SIRT1 mRNA (Fig. 4A) (Fig. 5A) . Feeding Lmna H222P/H222P mice with NR led to a marked increase of cardiac PARylation (Fig. 5A) . We next showed that mRNA (Fig. 5B) and protein (Fig. 5C ) levels of cardiac PARP-1, the most abundant isoform of the PARP enzyme family, were lowered in Lmna H222P/H222P mice compared with WT mice and increased after NR feeding. We performed immunoprecipitation using extracts of hearts from Lmna H222P/H222P mice and WT mice and antibody against poly(ADP-ribose). We found that the mice compared with WT mice (Fig. 5D) . Therefore, these results showed that the drop in NAD + cardiac content in Lmna
mice was altering PARP-1 activity.
Discussion
Altered NAD + metabolism through the salvage pathway has been described in muscular dystrophies (25, (29) (30) (31) and aging process (32) (33) (34) (35) (36) (37) . We expand the current knowledge by showing that altered NAD + salvage causes heart failure and inherited cardiomyopathy. We demonstrate that oral supplementation with NR, a vitamin B3 form and NAD + precursor, efficiently prevented development and progression of LMNA cardiomyopathy in mice. We show that NR supplementation significantly delayed disease progression even in mice that already manifested the disease, which is the time frame when medicated treatment would typically be started for patients. These results are remarkable, as they underline the utmost importance of specific vitamin co-factors, as modifiers of metabolism in cardiac disease, and emphasize the role of nutritional signaling in the pathogenesis of LMNA cardiomyopathy. The results presented in this study are in line with previous work showing that exogenous NAD + content blocks cardiac hypertrophy, (9, 11) . A recent study demonstrated that NR treatment transiently rescued the cardiomyopathy in iron deficiency mouse model (38) . Similarly, increasing the NAD + content using precursors of NAD + has been proven efficient to rescue hallmark of mitochondrial myopathy both in mouse (29) and human (39), as well as in aging (36, 40) . How decreased NAD + results in cardiac tissue injury in LMNA
cardiomyopathy is yet to be fully elucidated and this would need further investigation. We showed that PARylation is altered in LMNA cardiomyopathy, ensuing decreased cardiac NAD + . PARP enzymes bind and cleave NAD + to nicotinamide and charged PAR polymers on a large set of target proteins (41) . Given its DNA-binding zinc fingers (41,42) PARP-1 can be activated through DNA breaks (43) and irregular DNA structures (44) , and thus cleaves NAD + generating NAM and ADP-ribose. In the attempt to repair DNA lesions, PARP-1 activation takes place by adding ADP-ribose units to form chains of PAR covalently attached to acceptor proteins, among which PARP-1, to facilitate the DNA repair machinery (45, 46 shown that modulation of cardiac NAD + content using NR is a straightforward therapeutic strategy. Given that vitamin B3 supplement is potentially translatable into therapy, our work supports more studies on human to begin to evaluate the therapeutic benefits of increasing NAD + and assess the benefit of such therapy on LMNA cardiomyopathy. Accordingly, recent work described that normalization of NAD + content could be used as a pharmacologic strategy in failing heart (11, 47) and a clinical trial to assess the benefit of NR in systolic heart failure is on-going (NCT03423342). This novel therapy would need to be associated with reduced risks, particularly as the treatment may be needed for years. The translation from bench-to-bedside could be seen in years to come since precursors of NAD + [e.g. Acipimox (48, 49) , Nicobion, Nicorandil] have already been used in therapeutics (50) (51) (52) (53) . Recently, it has been shown that a single dose of NR resulted in significant increases in NAD + in healthy human volunteers (23) . Overall, our work provides adequate grounds for a therapeutic approach based on NR for patients with LMNA cardiomyopathy.
Experimental Procedures
Human heart tissue
Explanted hearts from human subjects with LMNA cardiomyopathy were obtained from Myobank-AFM from the lnstitut de Myologie (Paris, France mice were fed chow and housed in a disease-free barrier facility with 12 h light/12 h dark cycles. Chow supplemented with 0.25% NR (400 mg/kg) (Chromadex), as previously reported (27) , was formulated by Scientific Animal Food and Engineering. For postsymptomatic treatment, NR was delivered to Lmna H222P/H222P mice at a dose of 400/kg per day orally by gavage. NR was formulated in water and water was used as placebo. NAM was delivered to a concentration of 500 mg/kg every other day by intraperitoneal injection using a 27 G 5/8 syringe. NAM was formulated in physiologic serum and physiologic serum was used as placebo. For survival analysis, Lmna H222P/H222P mice were fed chow supplemented with 0.25% NR when they were 17 weeks of age and continued until they suffered from significant distress or died.
Echocardiography
Lmna H222P/H222P and WT mice were anesthetized with 0.75% isoflurane in O 2 and placed on a heating pad (25 • C). Echocardiography was performed using an ACUSON 128XP/10 ultrasound with an 11 MHz transducer applied to the chest wall. Cardiac ventricular dimensions and fractional shortening were measured in 2D mode and M-mode 3 times for the number of animals indicated. A 'blinded' echocardiographer, unaware of the genotype and the treatment, performed the examinations.
qPCR analysis
Total RNA was extracted using the RNeasy Mini kit (Qiagen). cDNA was synthesized using the SuperScript III synthesis system according to the manufacturer's instructions (Invitrogen). Real-time qPCR reactions were performed with SYBR Green I Master mix (Roche) using with the LightCycler 480 (Roche).
Relative levels of mRNA expression calculated using the C T method were normalized by comparison to housekeeping mRNA (54) . The listing of primers can be found in Supplementary Material Table S3 .
Immunoblotting
Mouse heart tissues were homogenized in sample extraction buffer (Cell Signaling) completed with deacetylation inhibitors cocktail (Santa Cruz Biotechnology) then separated by 10% SDSpolyacrylamide gel electrophoresis, transferred to nitrocellulose membranes and blotted with primary antibodies (Supplementary Material, Table S4 ). Secondary antibodies were horseradish peroxidate-conjugate (Jackson ImmunoResearch). Recognized proteins were visualized by enhanced chemiluminescence.
NAD + concentration quantification.
Fresh mouse tissues were homogenized and processed according to previous report (55) . The concentration of cardiac and liver NAD + was determined using a spectrophotometric assay as described previously (56) . Absorption measurements were carried out in 96-well plates by spectrophotometry (Tecan).
Statistics.
Values for real-time q-PCR, immunoblots and NAD + content were compared using an unpaired Student's t-test. Comparisons of echocardiographic parameters between groups of Lmna H222P/H222P mice (treated and untreated) were performed using a Welch t-test; to validate these results, a non-parametric test (MannWhitney) was performed and concordance checked. Statistical analyses were performed using Prism 6.0 software (Graphpad).
Supplementary Material
Supplementary Material is available at HMG online.
